In Q2 FY2026, Cardinal Health reported revenue of $65.6 billion, driven by strong performance in Pharmaceutical and Specialty Solutions. Operating earnings increased significantly, and both GAAP and non-GAAP EPS rose year over year, reflecting solid execution and margin expansion.

Cardinal Health delivered a robust Q1 FY26, marked by 22% revenue growth and significant improvement in both GAAP and non-GAAP earnings, prompting a raised outlook for the fiscal year.

Cardinal Health delivered a stable revenue of $60.2B in Q4 2025 and achieved a 13% increase in non-GAAP EPS to $2.08. Segment profits grew double digits across all divisions, driven by volume and acquisition growth. The company also raised FY26 EPS guidance.

Cardinal Health delivered solid Q3 results with flat revenue at $54.9 billion, but strong year-over-year growth in operating income and net income. Non-GAAP EPS rose 13%, driven by broad-based segment profitability and operational execution.

Cardinal Health reported a 13% increase in revenue to $50.5 billion for Q3 2023, driven by growth in the Pharmaceutical segment. GAAP operating earnings were $572 million, and GAAP diluted EPS was $1.34. Non-GAAP operating earnings increased by 11% to $606 million, and non-GAAP diluted EPS rose by 20% to $1.74. The company raised its full-year non-GAAP EPS and adjusted free cash flow guidance.

Cardinal Health initiated two voluntary field actions for select Cardinal Health Presource® Procedure Packs containing gowns due to concerns over sterility from an unapproved supplier. The company expects to record a $96 million charge in the second quarter of fiscal year 2020 related to these recalls.